Clinical Trials Logo

Acne clinical trials

View clinical trials related to Acne.

Filter by:

NCT ID: NCT02651220 Completed - Acne Clinical Trials

Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris

Start date: November 2015
Phase: Phase 3
Study type: Interventional

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of adapalene and benzoyl peroxide gel, 0.3%/2.5% (Actavis Laboratories UT, Inc.) to Epiduo® Forte (adapalene and benzoyl peroxide) gel 0.3%/2.5% (Galderma) in the treatment of Acne Vulgaris

NCT ID: NCT02593383 Completed - Acne Clinical Trials

Compound Adapalene and Clindamycin Hydrochloride Gel in Treatment of Patients With Acne

Start date: March 1, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

evaluate the safety and efficacy of Compound Adapalene and Clindamycin Hydrochloride Gel in treatment of chinese patients with acne.

NCT ID: NCT02550080 Recruiting - Psoriasis Clinical Trials

Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome

Start date: July 2015
Phase: Phase 4
Study type: Interventional

This Study is to evaluate the utility of prospective HLA-B*1301 screening on the incidence of dapsone hypersensitivity syndrome (DHS) in 3130 previously Dapsone(DDS)-naive patients. Those patients include allergic cutaneous vasculitis, urticaria, psoriasis, acne, bullous skin diseases, sterile pustulosis, leprosy, pneumocystis pneumonia and any other patients who need dapsone administration. The study has two (co-primary) objectives: i) to determine if screening for HLA-B*1301 prior to DDS-containing treatment results in a lower incidence of clinically-suspected DHS versus current standard of care (no genetic screening) and ii) to determine if screening for HLA-B*1301 prior to DDS-containing treatment results in a significantly lower incidence of immunologically-confirmed DHS versus current standard of care (no genetic screening or patch testing). The study consists of up to a 5-day screening period, a randomised observation period (Day 1 through Week 6) and, for subjects experiencing a suspected DHS and a subset of DDS-tolerant subjects, an epicutaneous patch test (EPT) assessment period. Eligible subjects will be randomised to one of two study arms: a Current Standard of Care Arm (no prospective genetic screening: Control) and a Genetic Screening Arm (prospective genetic screening: Case). Subjects identified as HLA-B*1301 positive in the prospective Genetic Screening Arm will not receive dapsone and will be excluded from further study. Subjects who experience suspected DHS during the 6-week observation would be withdrawn from dapsone and undergo EPT patch testing 6 weeks later.

NCT ID: NCT02525549 Completed - Acne Clinical Trials

Comparative Safety and Bioequivalence of Two Treatments in the Treatment of Acne Vulgaris

Start date: December 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the safety and bioequivalence of Perrigo's product to an FDA approved product for the treatment acne vulgaris.

NCT ID: NCT02515305 Completed - Acne Clinical Trials

Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris

Start date: July 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment acne vulgaris

NCT ID: NCT02457520 Completed - Acne Clinical Trials

ABSORICA in Patients With Severe Recalcitrant Nodular Acne

Start date: January 21, 2015
Phase: Phase 4
Study type: Interventional

This is an uncontrolled, open-label study being conducted in approximately 200 healthy males, non-pregnant, non-nursing females, age 12 to 45 years, with severe recalcitrant nodular acne. ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day will be administered for 4 weeks followed by 1.0 mg/kg/day for 16 weeks. Female subjects consenting to use two forms of birth control or abstinence are included.

NCT ID: NCT02457000 Completed - Healthy Clinical Trials

Sleep, Circadian Rhythm & Skin Health

Start date: March 2015
Phase:
Study type: Observational

The purpose of this study is to explore the mechanisms behind how sleep quality may affect skin aging, skin integrity and skin disease.

NCT ID: NCT02431494 Terminated - Acne Vulgaris Clinical Trials

Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris

Start date: October 30, 2014
Phase: N/A
Study type: Interventional

Acne vulgaris is a multifactorial, highly prevalent dermatologic condition that results in visible lesions that can be quite disfiguring. Consequently, individuals with acne often suffer from a wide range of psychological manifestations. Although there is consensus that combination therapy is most effective in treating acne, researchers are constantly striving to develop new treatment. Microcurrent therapy (MCT) is a non-invasive modality that has successfully been used to promote wound healing and has been routinely used in aesthetics. Use of MCT alone or in combination with current successful treatment such as blue light phototherapy (BLP), may hold promise for acne treatment. The investigators propose to conduct a small randomized control trial to determine the safety and preliminary efficacy of a novel combination therapy to treat acne vulgaris. The investigators will recruit up to 60 males and females and randomly assign them to one of 3 arms: 1) BLP; 2) MCT; and combination therapy (BLP and MCT). The investigators will assess physiological parameters (number of acne lesions, amount of sebum produced, degree of acne severity) and psychosocial factors (dermatologic quality of life, social anxiety, depressive symptomatology, self-esteem). Participants will complete a baseline assessment prior to initiating treatment and a follow-up assessment at 4 weeks post termination of treatment. The investigators will conduct intermediary assessments at weeks 3 and 5 and 1 week post termination of the treatment. The investigators will use measures of central tendency to describe the sample and repeated measures analysis of variance to compute the main and interaction effects.

NCT ID: NCT02307266 Completed - Acne Clinical Trials

Patient Education in Adherence on Acne (PEAce)

Start date: November 2014
Phase: Phase 4
Study type: Interventional

This is a multi-center, randomised and controlled study in subjects with acne vulgaris. The main objective of this study is to evaluate the effect of a supplementary patient education intervention (in addition to the standard-of-care patient education) on treatment adherence and satisfaction among acne patients receiving once-daily EpiduoTM gel treatment in primary care clinics.

NCT ID: NCT02250859 Completed - Acne Clinical Trials

A Pharmacokinetic Study of Minocycline in Male and Female Volunteers

Start date: September 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the pharmakokinetic profile of Minocycline in FMX-101 4% foam product in male and female some of which are with acne